Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
Loading
Year-over-year SG&A expense growth
Latest
90.27%
↑ 88% vs avg
Percentile
P100
Near historical high
Streak
2 yr
Consecutive growthAccelerating
Average
48.03%
Historical baseline
| Period | Value |
|---|---|
| 2024 | 90.27% |
| 2023 | 53.82% |
| 2022 | 0.00% |